Evidence map›Paper›PMID 27548442›Full record

ArticlePloS one2016

Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.

Christian Ruiz, Stefan Kustermann, Elina Pietilae, Tatjana Vlajnic, Betty Baschiera, Leila Arabi, Thomas Lorber, Martin Oeggerli, Spasenija Savic, Ellen Obermann and 5 more

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Christian RuizInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Stefan KustermannPharmaceutical Sciences, Roche Innovation Centre Basel, Basel, Switzerland.
Elina PietilaePharmaceutical Sciences, Roche Innovation Centre Basel, Basel, Switzerland.
Tatjana VlajnicInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Betty BaschieraInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Leila ArabiInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Thomas LorberInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Martin OeggerliInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Spasenija SavicInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Ellen ObermannInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Thomas SingerPharmaceutical Sciences, Roche Innovation Centre Basel, Basel, Switzerland.
Sacha I RothschildDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Alfred ZippeliusDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Adrian B RothPharmaceutical Sciences, Roche Innovation Centre Basel, Basel, Switzerland.
Lukas BubendorfInstitute for Pathology, University Hospital Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of patients' own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose since they have already adapted to the liquid environment in the patient and do not depend on a stromal cell compartment. Aim of this study was to develop a systematic approach for the in-vitro culture of MPEs to analyze the effect of chemotherapeutic as well as targeted drugs.

methodsMPEs from patients with solid tumors were selected for this study. After morphological and molecular characterization, they were cultured in medium supplemented with patient-derived sterile-filtered effusion supernatant. Growth characteristics were monitored in real-time using the xCELLigence system. MPEs were treated with a targeted therapeutic (erlotinib) according to the mutational status or chemotherapeutics based on the recommendation of the oncologists.

resultsWe have established a robust system for the ex-vivo culture of MPEs and the application of drug tests in-vitro. The use of an antibody based magnetic cell separation system for epithelial cells before culture allowed treatment of effusions with only moderate tumor cell proportion. Experiments using drugs and drug-combinations revealed dose-dependent and specific growth inhibitory effects of targeted drugs.

conclusionsWe developed a new approach for the ex-vivo culture of MPEs and the application of drug tests in-vitro using real-time measuring of cell growth, which precisely reproduced the effect of clinically established treatments by standard chemotherapy and targeted drugs. This sets the stage for future studies testing agents against specific targets from genomic profiling of metastatic tumor cells and multiple drug-combinations in a personalized manner.

Indexed as

AgedAntineoplastic AgentsCisplatinCrizotinibDose-Response Relationship, DrugDrug CombinationsDrug Screening Assays, AntitumorHumansImmunomagnetic SeparationMaleMiddle AgedPemetrexedPleural Effusion, MalignantPrecision MedicinePrimary Cell CulturePyrazolesAntineoplastic AgentsCisplatinCrizotinibDrug CombinationsPemetrexedPyrazolesPyridines

Identifiers

PMID27548442
PMCPMC4993361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.